{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:22:11Z","timestamp":1788398531644,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"am","delay-in-days":345,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ijcard.2020.10.028","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T14:10:10Z","timestamp":1602857410000},"page":"255-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Spontaneous reported cardiotoxicity induced by lopinavir\/ritonavir in COVID-19. An alleged past-resolved problem"],"prefix":"10.1016","volume":"324","author":[{"given":"Audrey","family":"Fresse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Viard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Romani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Lepelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Rocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milou-Daniel","family":"Drici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2020.10.028_bb0005","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","article-title":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture","volume":"58","author":"de Wilde","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0010","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1021\/acs.biochem.0c00160","article-title":"Why are Lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms","volume":"59","author":"Nutho","year":"2020","journal-title":"Biochemistry."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0015","author":"Dorward"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0020","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/TCRM.S3285","article-title":"Lopinavir\/ritonavir in the treatment of HIV-1 infection: a review","volume":"4","author":"Chandwani","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0025","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1071\/SH09005","article-title":"Transient cardiac arrhythmias related to lopinavir\/ritonavir in two patients with HIV infection","volume":"6","author":"Chaubey","year":"2009","journal-title":"Sex. Health"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0030","first-page":"415","article-title":"Bloqueo auriculoventricular completo en paciente tratado con lopinavir\/ritonavir","volume":"20","author":"Jim\u00e9nez","year":"2002","journal-title":"Enfermedades Infecc. Microbiol. Cl\u00ednica."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0035","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1086\/341975","article-title":"Serious Bradyarrhythmia that was possibly induced by Lopinavir-ritonavir in 2 patients with acquired immunodeficiency syndrome","volume":"35","author":"Kikuchi","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0040","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ijcard.2014.11.090","article-title":"A sudden cardiac death induced by sildenafil and sexual activity in an HIV patient with drug interaction, cardiac early repolarization, and arrhythmogenic right ventricular cardiomyopathy","volume":"179","author":"Kobayashi","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0045","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1365-2125.2010.03849.x","article-title":"Extreme bradycardia due to multiple drug\u2013drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir\u2013ritonavir","volume":"71","author":"Puech","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0050","doi-asserted-by":"crossref","first-page":"613","DOI":"10.11150\/kansenshogakuzasshi.87.613","article-title":"Sick sinus syndrome possibly due to lopinavir-ritonavir: report of two cases","volume":"87","author":"Sasaki","year":"2013","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0055","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/01.aids.0000183942.05849.1b","article-title":"Bradycardia\u2013tachycardia syndrome induced by lopinavir\u2013ritonavir in a patient with AIDS","volume":"19","author":"Yotsumoto","year":"2005","journal-title":"AIDS."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0060","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vascn.2016.03.009","article-title":"An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel","volume":"81","author":"Crumb","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0065","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(05)17950-1","article-title":"Blockade of HERG channels by HIV protease inhibitors","volume":"365","author":"Anson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0070","first-page":"185","article-title":"Cardiac K+ channels and drug-acquired long QT syndrome","volume":"55","author":"Drici","year":"2000","journal-title":"Th\u00e9rapie"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0075","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/QAD.0b013e328341dcc0","article-title":"Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations","volume":"25","author":"Soliman","year":"2011","journal-title":"AIDS Lond. Engl."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0080","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1310\/hct1005-328","article-title":"Electrocardiogram abnormalities with Atazanavir and Lopinavir\/ritonavir","volume":"10","author":"Rathbun","year":"2009","journal-title":"HIV Clin. Trials."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0085","doi-asserted-by":"crossref","first-page":"P95","DOI":"10.1186\/1758-2652-11-S1-P95","article-title":"Evaluation of the impact of lopinavir\/ritonavir (LPV\/r) and ritonavir (RTV) on QTcF: results of a thorough QT study","volume":"11","author":"Klein","year":"2008","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0090","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvaa106","article-title":"COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options","author":"Guzik","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0095","article-title":"Hypokalemia and Clinical Implications in Patients with Coronavirus Disease 2019 (COVID-19)","author":"Chen","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0100","series-title":"\u201cOff-Label\u201d Use of Hydroxychloroquine, Azithromycin, Lopinavir-Ritonavir and Chloroquine in COVID-19: A Survey of Cardiac Adverse Drug Reactions by the French Network of Pharmacovigilance Centers, Therapies","author":"G\u00e9rard","year":"2020"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0105","first-page":"111","article-title":"Imputabilit\u00e9 des effets inattendus ou toxiques des m\u00e9dicaments: actualisation de la m\u00e9thode utilis\u00e9e en France","volume":"40","author":"Begaud","year":"1985","journal-title":"Th\u00e9rapie."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0110","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.therap.2016.02.010","article-title":"Causality assessment in pharmacovigilance: the French method and its successive updates","volume":"71","author":"Miremont-Salam\u00e9","year":"2016","journal-title":"Therapies."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0115","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/01.ftd.0000211825.57984.41","article-title":"An update on therapeutic drug monitoring for antiretroviral drugs","volume":"28","author":"Back","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0120","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1161\/CIRCULATIONAHA.118.033943","article-title":"Determination and Interpretation of the QT Interval","volume":"138","author":"Suzanne","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0125","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2008.12.014","article-title":"Endorsed by the International Society for Computerized Electrocardiology","volume":"53","author":"Rautaharju","year":"2009","journal-title":"J. Am. Coll. Cardiol"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0130","unstructured":"CredibleMeds, (n.d.). https:\/\/www.crediblemeds.org\/ (accessed April 29, 2020)."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0135","unstructured":"MedDRA. Medical dictionary for regulatory activities., (n.d.). https:\/\/www.meddra.org\/ (accessed June 2, 2020)."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0140","series-title":"R: A language and environment for statistical computing","author":"R Development Core Team","year":"2005"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0145","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/INF.0b013e3181acd17e","article-title":"Twin preterm neonates with cardiac toxicity related to lopinavir\/ ritonavir therapy","volume":"28","author":"McArthur","year":"2009","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0150","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/jcph.838","article-title":"Evidence for the hERG liability of antihistamines, antipsychotics, and anti-infective agents: a systematic literature review from the ARITMO project","volume":"57","author":"Hazell","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0155","doi-asserted-by":"crossref","first-page":"23587","DOI":"10.1074\/jbc.M200448200","article-title":"Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block","volume":"277","author":"S\u00e1nchez-Chapula","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0160","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jama.280.20.1774","article-title":"Cardiac actions of erythromycin: influence of female sex","volume":"280","author":"Drici","year":"1998","journal-title":"JAMA."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0165","unstructured":"VigiLyze, (n.d.). https:\/\/vigilyze.who-umc.org\/ (accessed September 8, 2020)."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0170","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0175","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cpt.1303","article-title":"Assessment of multi-Ion Channel block in a phase I randomized study design: results of the CiPA phase I ECG biomarker validation study","volume":"105","author":"Vicente","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0180","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/jac\/dkq468","article-title":"Pharmacokinetics of plasma lopinavir\/ritonavir following the administration of 400\/100 mg, 200\/150 mg and 200\/50 mg twice daily in HIV-negative volunteers","volume":"66","author":"Jackson","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0185","series-title":"Comparison of Lopinavir and Ritonavir Tablet and Soft Gelatin Capsule (SGC) Pharmacokinetics in Antiretroviral-Na\u00efve HIV-1 Infected Subjects, in: Abbott","author":"Klein","year":"2008"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0190","doi-asserted-by":"crossref","unstructured":"S. Baldelli, M. Corbellino, E. Clementi, D. Cattaneo, C. Gervasoni, Lopinavir\/ritonavir in COVID-19 patients: maybe yes, but at what dose?, J. Antimicrob. Chemother. (n.d.). doi:https:\/\/doi.org\/10.1093\/jac\/dkaa190.","DOI":"10.1093\/jac\/dkaa190"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0195","doi-asserted-by":"crossref","first-page":"104866","DOI":"10.1016\/j.antiviral.2020.104866","article-title":"Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection","volume":"181","author":"Venisse","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0200","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkaa195","article-title":"Lopinavir pharmacokinetics in COVID-19 patients","author":"Gregoire","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0205","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01177-20","article-title":"Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations","volume":"64","author":"Marzolini","year":"2020","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0210","first-page":"215","article-title":"Peeraphatdit, Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol","volume":"9","author":"Naksuk","year":"2020","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0215","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.120.047293","article-title":"COVID-19, arrhythmic risk, and inflammation: mind the gap!","volume":"142","author":"Lazzerini","year":"2020","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0220","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.acvd.2020.04.001","article-title":"Response to the editorial \u201cCOVID-19 in patients with cardiovascular diseases\u201d: Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: a potential risk of Torsades de pointes","volume":"113","author":"Funck-Brentano","year":"2020","journal-title":"Arch. Cardiovasc. Dis."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0225","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2020.1096","article-title":"Cardiac Involvement in a Patient with Coronavirus Disease 2019 (COVID-19)","author":"Inciardi","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0230","series-title":"Cardiovascular Manifestations and Treatment Considerations in Covid-19","author":"Kang","year":"2020"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0235","series-title":"Diarrhea during COVID-19 Infection: Pathogenesis, Epidemiology, Prevention and Management","author":"D\u2019Amico","year":"2020"},{"key":"10.1016\/j.ijcard.2020.10.028_bb0240","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/fcp.12582","article-title":"Estimates of population-based incidence of malignant arrhythmias associated with medication use \u2013 a narrative review","volume":"34","author":"Drici","year":"2020","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30117-X","article-title":"Sex difference and smoking predisposition in patients with COVID-19","volume":"8","author":"Cai","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ijcard.2020.10.028_bb0250","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2165\/00002018-200124080-00002","article-title":"Is gender a risk factor for adverse drug reactions?","volume":"24","author":"Drici","year":"2001","journal-title":"Drug Saf."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527320339814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527320339814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:49:42Z","timestamp":1759092582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527320339814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":50,"alternative-id":["S0167527320339814"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.10.028","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spontaneous reported cardiotoxicity induced by lopinavir\/ritonavir in COVID-19. An alleged past-resolved problem","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}